A significant clinical finding has emerged from analysis of the SYMPLIFY study cohort: patients with ‘false positive’ multi-cancer early detection test results demonstrated a 7.9% cancer diagnosis rate within 12 months, compared to only 1.0% among those with true negative results.
This eight-fold difference challenges conventional interpretation of test results and suggests that a substantial proportion of ‘false positives’ may represent genuine early cancer detection through circulating cell-free DNA analysis. Among 368 participants with positive results, approximately 29 received subsequent cancer diagnoses, indicating that these tests may capture cancers not identified through standard diagnostic pathways.
The data supports the clinical utility of MCED technology as an adjunctive diagnostic tool in symptomatic populations.
Was this article helpful?
